Wall Street brokerages expect PRA Health Sciences Inc (NASDAQ:PRAH) to post earnings of $1.03 per share for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for PRA Health Sciences’ earnings. The highest EPS estimate is $1.04 and the lowest is $1.01. PRA Health Sciences reported earnings per share of $0.71 during the same quarter last year, which would indicate a positive year over year growth rate of 45.1%. The firm is scheduled to report its next earnings report after the market closes on Wednesday, February 21st.

On average, analysts expect that PRA Health Sciences will report full-year earnings of $3.31 per share for the current fiscal year, with EPS estimates ranging from $3.30 to $3.32. For the next financial year, analysts forecast that the business will report earnings of $4.09 per share, with EPS estimates ranging from $3.80 to $4.30. Zacks’ EPS calculations are an average based on a survey of analysts that cover PRA Health Sciences.

Several equities research analysts recently commented on PRAH shares. SunTrust Banks reiterated a “buy” rating and set a $101.00 price target on shares of PRA Health Sciences in a research note on Friday, October 27th. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, December 27th. Jefferies Group reiterated a “buy” rating and set a $95.00 price target on shares of PRA Health Sciences in a research note on Thursday, October 26th. Barclays started coverage on shares of PRA Health Sciences in a research note on Monday, December 11th. They set an “overweight” rating and a $94.00 price target on the stock. Finally, Zacks Investment Research lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. PRA Health Sciences currently has an average rating of “Buy” and a consensus price target of $92.31.

Shares of PRA Health Sciences (NASDAQ:PRAH) traded down $0.76 during trading hours on Tuesday, reaching $88.14. 325,225 shares of the company traded hands, compared to its average volume of 409,780. PRA Health Sciences has a 12-month low of $57.72 and a 12-month high of $95.90. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01. The firm has a market cap of $5,633.57, a price-to-earnings ratio of 49.24, a P/E/G ratio of 1.20 and a beta of 0.32.

In other PRA Health Sciences news, VP Linda Baddour sold 67,000 shares of PRA Health Sciences stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total value of $6,048,090.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP David W. Dockhorn sold 72,850 shares of PRA Health Sciences stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $90.83, for a total transaction of $6,616,965.50. Following the completion of the transaction, the executive vice president now owns 72,850 shares in the company, valued at $6,616,965.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 212,700 shares of company stock worth $19,282,021. 2.10% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Magnetar Financial LLC purchased a new stake in shares of PRA Health Sciences in the third quarter valued at about $5,010,000. Sei Investments Co. boosted its holdings in shares of PRA Health Sciences by 8.5% in the third quarter. Sei Investments Co. now owns 15,899 shares of the medical research company’s stock valued at $1,212,000 after acquiring an additional 1,245 shares in the last quarter. Alyeska Investment Group L.P. boosted its holdings in shares of PRA Health Sciences by 12.0% in the third quarter. Alyeska Investment Group L.P. now owns 463,941 shares of the medical research company’s stock valued at $35,338,000 after acquiring an additional 49,693 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of PRA Health Sciences in the fourth quarter valued at about $439,000. Finally, Jennison Associates LLC boosted its holdings in shares of PRA Health Sciences by 238.6% in the fourth quarter. Jennison Associates LLC now owns 11,202 shares of the medical research company’s stock valued at $1,020,000 after acquiring an additional 7,894 shares in the last quarter. Institutional investors own 97.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/20/1168665.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply